Team Blitz India
NEW DELHI: Piramal Pharma posted a 102 per cent Year-on-Year (YoY) increase in Profit After Tax (PAT) during the Q4FY24, reaching Rs 101.27 crore. The company also posted an 18 per cent increase in its consolidated revenue from operations, which came in at Rs 2,552.36 crore. This increase in PAT was attributed to good performance in the CDMO business, differentiated offerings and capacity expansion.
On a sequential basis, the company’s profit jumped more than nine-fold. The revenue also rose by 30.31 per cent. The Earnings before Interest, Tax, Appreciation and Amortisation (EBITDA) rose 48 per cent YoY reaching Rs 556 crore.
Speaking on the results, Nandini Piramal, chairperson of Piramal Pharma, said, “FY24 has been a strong year for the company with all round improvement, mainly driven by our CDMO business that delivered a robust 19 percent YoY revenue growth.”
